Novavax, Inc. (FRA:NVV1)
5.81
-0.20 (-3.34%)
Dec 1, 2025, 4:48 PM CET
Novavax Revenue
Novavax had revenue of $70.45M USD in the quarter ending September 30, 2025, a decrease of -16.64%. This brings the company's revenue in the last twelve months to $1.06B, up 20.27% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.06B
Revenue Growth
+20.27%
P/S Ratio
1.03
Revenue / Employee
$1.12M
Employees
952
Market Cap
935.14M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
| Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
| Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
| Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
| Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
| Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
| Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
| Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
| Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
| Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
| Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
| Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
| Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
| Dec 31, 2005 | 5.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Novavax News
- 10 days ago - Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
- 10 days ago - Novavax rises after a seven-day slide - Seeking Alpha
- 12 days ago - Notable Wednesday Option Activity: NVAX, BLK, MP - Nasdaq
- 12 days ago - Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - JP Morgan Lowers Price Target for NVAX, Maintains Underweight Rating | NVAX Stock News - GuruFocus
- 17 days ago - Oversold Conditions For Novavax (NVAX) - Nasdaq
- 19 days ago - Shah Capital pushes for Novavax sale, warns of proxy fight - Reuters
- 19 days ago - Novavax to Participate in Jefferies London Healthcare Conference - PRNewsWire